Shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.59 and traded as low as $5.14. Evoke Pharma shares last traded at $5.53, with a volume of 15,621 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Evoke Pharma in a research note on Saturday. They issued a “sell” rating on the stock.
Get Our Latest Analysis on EVOK
Evoke Pharma Trading Up 3.6 %
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The company had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- Earnings Per Share Calculator: How to Calculate EPS
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How is Compound Interest Calculated?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is a support level?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.